» Articles » PMID: 30071877

Implications of Population-level Immunity for the Emergence of Artemisinin-resistant Malaria: a Mathematical Model

Overview
Journal Malar J
Publisher Biomed Central
Specialty Tropical Medicine
Date 2018 Aug 4
PMID 30071877
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Artemisinin-resistant Plasmodium falciparum has emerged in the Greater Mekong Subregion, an area of relatively low transmission, but has yet to be reported in Africa. A population-based mathematical model was used to investigate the relationship between P. falciparum prevalence, exposure-acquired immunity and time-to-emergence of artemisinin resistance. The possible implication for the emergence of resistance across Africa was assessed.

Methods: The model included human and mosquito populations, two strains of malaria ("wild-type", "mutant"), three levels of human exposure-acquired immunity (none, low, high) with two types of immunity for each level (sporozoite/liver stage immunity and blood-stage/gametocyte immunity) and drug pressure based on per-capita treatment numbers.

Results: The model predicted that artemisinin-resistant strains may circulate up to 10 years longer in high compared to low P. falciparum prevalence areas before resistance is confirmed. Decreased time-to-resistance in low prevalence areas was explained by low genetic diversity and immunity, which resulted in increased probability of selection and spread of artemisinin-resistant strains. Artemisinin resistance was estimated to be established by 2020 in areas of Africa with low (< 10%) P. falciparum prevalence, but not for 5 or 10 years later in moderate (10-25%) or high (> 25%) prevalence areas, respectively.

Conclusions: Areas of low transmission and low immunity give rise to a more rapid expansion of artemisinin-resistant parasites, corroborating historical observations of anti-malarial resistance emergence. Populations where control strategies are in place that reduce malaria transmission, and hence immunity, may be prone to a rapid emergence and spread of artemisinin-resistant strains and thus should be carefully monitored.

Citing Articles

Therapeutic efficacy and safety of artemether-lumefantrine combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria at Teda Health Centre, Northwest Ethiopia, 2022/23.

Woldesenbet D, Birhanie M, Abere A, Zeleke A, Bezabih M, Semaw M Malar J. 2024; 23(1):266.

PMID: 39215366 PMC: 11363363. DOI: 10.1186/s12936-024-05082-y.


Indigenous emergence and spread of C469Y artemisinin-resistant in Uganda.

Awor P, Coppee R, Khim N, Rondepierre L, Roesch C, Khean C Antimicrob Agents Chemother. 2024; 68(8):e0165923.

PMID: 39028193 PMC: 11304714. DOI: 10.1128/aac.01659-23.


Assessing the relationship between malaria incidence levels and meteorological factors using cluster-integrated regression.

Amadi M, Erandi K BMC Infect Dis. 2024; 24(1):664.

PMID: 38961345 PMC: 11220975. DOI: 10.1186/s12879-024-09570-z.


Impact of different mutations on Kelch13 protein levels, ART resistance, and fitness cost in parasites.

Behrens H, Schmidt S, Henshall I, Lopez-Barona P, Peigney D, Sabitzki R mBio. 2024; 15(6):e0198123.

PMID: 38700363 PMC: 11237660. DOI: 10.1128/mbio.01981-23.


Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.

Mihreteab S, Platon L, Berhane A, Stokes B, Warsame M, Campagne P N Engl J Med. 2023; 389(13):1191-1202.

PMID: 37754284 PMC: 10539021. DOI: 10.1056/NEJMoa2210956.


References
1.
Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

2.
Wongsrichanalai C, Meshnick S . Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis. 2008; 14(5):716-9. PMC: 2600243. DOI: 10.3201/eid1405.071601. View

3.
Plowe C, Roper C, Barnwell J, Happi C, Joshi H, Mbacham W . World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J. 2007; 6:121. PMC: 2008207. DOI: 10.1186/1475-2875-6-121. View

4.
Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, van Gemert G . The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One. 2010; 5(11):e14114. PMC: 2993929. DOI: 10.1371/journal.pone.0014114. View

5.
Ataide R, Ashley E, Powell R, Chan J, Malloy M, OFlaherty K . Host immunity to and the assessment of emerging artemisinin resistance in a multinational cohort. Proc Natl Acad Sci U S A. 2017; 114(13):3515-3520. PMC: 5380044. DOI: 10.1073/pnas.1615875114. View